MA42442A - Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate - Google Patents
Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamateInfo
- Publication number
- MA42442A MA42442A MA42442A MA42442A MA42442A MA 42442 A MA42442 A MA 42442A MA 42442 A MA42442 A MA 42442A MA 42442 A MA42442 A MA 42442A MA 42442 A MA42442 A MA 42442A
- Authority
- MA
- Morocco
- Prior art keywords
- sup
- modulators
- glutamate receptor
- metabotropic glutamate
- sub
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical class C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal (AREA)
Abstract
<!--startfragment-->la présente invention concerne des composés de formule i dans laquelle r<sup>1</sup> est un alkyle inférieur ; r<sup>2</sup> est un phényle ou pyridinyle, l'atome n dans le groupe pyridinyle pouvant être à des positions différentes ; n est 0, 1 ou 2 ; v/u sont indépendamment l'un de l'autre o ou ch<sub>2</sub>, v et u ne pouvant pas être simultanément o ; et l est un groupe hétéroaryle à cinq ou six chaînons, ou un sel pharmaceutiquement acceptable ou un sel d'addition d'acide, un mélange racémique de ceux-ci, ou un énantiomère et/ou isomère optique et/ou stéréoisomère correspondant. Les composés peuvent être utilisés pour traiter la maladie de parkinson, l'anxiété, les vomissements, les troubles obsessionnels compulsifs, l'autisme, le cancer, la dépression et le diabète de type 2 ainsi que pour la neuroprotection.<!--endfragment-->
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176854 | 2015-07-15 | ||
| PCT/EP2016/066393 WO2017009275A1 (fr) | 2015-07-15 | 2016-07-11 | Dérivés d'éthynyle a titre de modulateurs du récepteur métabotropique du glutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42442A true MA42442A (fr) | 2018-05-23 |
| MA42442B1 MA42442B1 (fr) | 2019-07-31 |
Family
ID=53758003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42442A MA42442B1 (fr) | 2015-07-15 | 2016-07-11 | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10189848B2 (fr) |
| EP (1) | EP3322701B1 (fr) |
| JP (1) | JP6761821B2 (fr) |
| KR (1) | KR20180026438A (fr) |
| CN (1) | CN107580598B (fr) |
| AR (1) | AR105341A1 (fr) |
| AU (1) | AU2016292863B2 (fr) |
| CA (1) | CA2984711C (fr) |
| CL (1) | CL2018000036A1 (fr) |
| CO (1) | CO2017011174A2 (fr) |
| CR (1) | CR20180022A (fr) |
| DK (1) | DK3322701T3 (fr) |
| ES (1) | ES2733468T3 (fr) |
| HR (1) | HRP20191139T1 (fr) |
| HU (1) | HUE045145T2 (fr) |
| IL (1) | IL255096B (fr) |
| LT (1) | LT3322701T (fr) |
| MA (1) | MA42442B1 (fr) |
| MX (1) | MX374409B (fr) |
| PE (1) | PE20180356A1 (fr) |
| PH (1) | PH12018500106A1 (fr) |
| PL (1) | PL3322701T3 (fr) |
| PT (1) | PT3322701T (fr) |
| RS (1) | RS58929B1 (fr) |
| RU (1) | RU2721776C9 (fr) |
| SI (1) | SI3322701T1 (fr) |
| TR (1) | TR201909160T4 (fr) |
| TW (1) | TWI612962B (fr) |
| UA (1) | UA120463C2 (fr) |
| WO (1) | WO2017009275A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| UA120463C2 (uk) | 2015-07-15 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як модулятори метаботропного рецептора глутамату |
| WO2018015235A1 (fr) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Dérivés d'éthynyle |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| KR20210039368A (ko) | 2018-07-26 | 2021-04-09 | 도메인 테라퓨틱스 | 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (fr) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| CA3157361A1 (fr) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr |
| WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
| CA3163875A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022221170A1 (fr) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Polythérapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4 |
| CA3220155A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| AU2024239979A1 (en) * | 2023-03-10 | 2025-09-18 | Brightseed, Inc. | Compositions and methods for modulating stress and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| PL1891075T3 (pl) | 2005-05-24 | 2011-12-30 | Merck Serono Sa | Spiropochodne tricykliczne jako modulatory CRTH2 |
| WO2008027466A1 (fr) | 2006-08-31 | 2008-03-06 | Schering Corporation | Derives d'hydantoine utiles en tant qu'agents antibacteriens |
| KR20100033981A (ko) | 2007-06-03 | 2010-03-31 | 벤더르빌트 유니버시티 | 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법 |
| WO2009094755A1 (fr) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anticorps monoclonaux contre les virus d'ebola et de marburg |
| JP5518899B2 (ja) | 2009-01-19 | 2014-06-11 | フォンダツィオネ・イルクス・カ’グランダ−オスペダレ・マジョーレ・ポリクリニコ | 抗微生物活性を有するメラノコルチンアナログ |
| US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| EP2702050B1 (fr) | 2011-04-26 | 2016-05-18 | F.Hoffmann-La Roche Ag | Dérivés de pyrazolidine-3-one |
| HRP20150555T1 (hr) | 2011-04-26 | 2015-07-03 | F. Hoffmann - La Roche Ag | Derivati etinila kao pozitivni alosterijski modulatori za mglur5 |
| WO2012162635A1 (fr) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Modulateurs des récepteurs 5 métabotropiques du glutamate et leurs procédés d'utilisation |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| AU2013292142B2 (en) | 2012-07-17 | 2017-03-09 | F. Hoffmann-La Roche Ag | Arylethynyl derivatives |
| CN104718191B (zh) | 2012-10-18 | 2016-06-29 | 霍夫曼-拉罗奇有限公司 | 作为mglur5受体活性调节剂的乙炔基衍生物 |
| MY171517A (en) | 2012-10-18 | 2019-10-16 | Hoffmann La Roche | Ethynyl derivatives as modulators of mglur5 receptor activity |
| WO2014124560A1 (fr) | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Régulateurs de mglur |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| EA029352B1 (ru) * | 2013-09-25 | 2018-03-30 | Ф. Хоффманн-Ля Рош Аг | Производные этинила |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| AU2015218909A1 (en) | 2014-02-19 | 2016-08-04 | Emergent Biosolutions Canada Inc. | Marburg monoclonal antibodies |
| HUE041392T2 (hu) | 2014-02-25 | 2019-05-28 | Hoffmann La Roche | Etinil származékok |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| JP2017531642A (ja) | 2014-10-03 | 2017-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | エボラ糖タンパク質に結合する抗体およびその使用 |
| CN107207481B (zh) | 2015-03-19 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物 |
| UA120463C2 (uk) | 2015-07-15 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як модулятори метаботропного рецептора глутамату |
| WO2018015235A1 (fr) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Dérivés d'éthynyle |
-
2016
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/fr not_active Ceased
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en not_active Ceased
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/fr active Active
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 HR HRP20191139TT patent/HRP20191139T1/hr unknown
- 2016-07-11 MX MX2018000592A patent/MX374409B/es active IP Right Grant
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko active Pending
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 CA CA2984711A patent/CA2984711C/fr active Active
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2021
- 2021-05-09 US US17/315,349 patent/US12006323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42442A (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA38272A1 (fr) | Peptides en tant qu'agonistes de l'oxytocine | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| PH12012500690A1 (en) | Positive allosteric modulators (pam) | |
| MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA35113B1 (fr) | 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5 | |
| MA38885A1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
| EA201590699A1 (ru) | Производные этинила в качестве модуляторов активности рецептора mglur5 | |
| MA33802B1 (fr) | Dérivés d'éthynyle | |
| MA54447B1 (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer | |
| TN2010000025A1 (fr) | Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| MA45665B1 (fr) | Dérivés d'éthynyle | |
| IN2014CN02477A (fr) | ||
| EA201590676A1 (ru) | Производные этинила в качестве модуляторов активности рецептора mglur5 | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| RU2008152764A (ru) | Биарилкарбоксиариламиды как модуляторы ванилоидного рецептора типа 1 | |
| MA60976B1 (fr) | Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine | |
| MA34251B1 (fr) | Derives amido-tropane | |
| TH1701007595A (th) | อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์ |